血脂管理与ASCVD的回顾与展望  

Retrospect and prospect of blood lipid management and ASCVD

作　　者：彭道泉[1] 杨阳[1] PENG Daoquan;YANG Yang(Department of Cardiology,The Second Xiangya Hospital of Central South University,Changsha,410011,China)

机构地区：[1]中南大学湘雅二医院心内科,长沙410011

出　　处：《临床心血管病杂志》2020年第9期783-786,共4页Journal of Clinical Cardiology

摘　　要：更新的血脂指南中,一级预防危险分层引入增强的危险因素,二级预防中动脉粥样硬化性心血管疾病(ASCVD)风险再分层,低密度脂蛋白胆固醇(LDL-C)目标值进一步降低。联合降脂已成为趋势,用药种类、给药方式及治疗靶点均有全新呈现。In the updated blood lipid guidelines, the risk stratification of primary prevention introduces enhanced risk factors, the risk of atherosclerotic cardiovascular disease(ASCVD) in secondary prevention is further stratified, and the target value of low-density lipoprotein cholesterol(LDL-C) decreases further. Combined lipid-lowering has become a trend. The types of medications, methods of administration and therapeutic targets have been newly presented.

关 键 词：动脉粥样硬化性心血管疾病 低密度脂蛋白胆固醇 脂蛋白(a) 前蛋白转化酶枯草溶菌素9抑制剂 血管生成素样因子3 鱼油 

分 类 号：R541.4[医药卫生—心血管疾病]